Merck's Scheuble: Being a Conglomerate Works
Executive Summary
Professor Bernhard Scheuble, PhD, chairman and CEO of Merck KGAA, explains how the German conglomerate is dealing with current pressures on its branded business, and why being diversified across ethicals, generics and fine chemicals is an advantage, not a distraction.
You may also be interested in...
NicOx/AstraZeneca: Transparency vs. Partnering
AstraZeneca's news that nitric oxide donator AZD 3582 had failed to reach a primary end-point in a Phase II trial sent originator NicOx's shares plummeting, as investors lost faith in the biotech's entire platform. NicOx is disputing the data's accuracy in an attempt to salvage investor confidence--and to survive. The events highlight the tension between Big Pharma's duties to investor transparency and to protect its biotech partners. They're also a reminder to biotechs that there's more to deals than just royalties.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.